MajorVitamin K antagonist anticoagulants×Antiplatelet agents – P2Y12 receptor inhibitors
Updated · Methodology
Mechanism
Clopidogrel inhibits platelet aggregation (clopidogrel summary of product characteristics, SmPC, European Medicines Agency, EMA), while acenocoumarol acts through vitamin K, which the liver needs for gamma-carboxylation of the prothrombin complex factors (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). These effects on haemostasis are independent and add up, so bleeding with the combination can be more severe (EMA). Pharmacokinetic data exist only for warfarin. In people on long-term warfarin, clopidogrel 75 mg a day did not change the pharmacokinetics of S-warfarin or the international normalised ratio (INR), but the risk of bleeding increased (EMA; clopidogrel label, US Food and Drug Administration, FDA). Clopidogrel inhibits platelets for their whole lifespan, 7–10 days (FDA).
Symptoms
The main risk is bleeding. On clopidogrel, bruising happens more easily and bleeding takes longer than usual to stop (clopidogrel label, US Food and Drug Administration, FDA). Bleeding with clopidogrel was reported mainly in the first month of treatment and included intracranial bleeding, in some cases fatal (clopidogrel summary of product characteristics, SmPC, European Medicines Agency, EMA). Warning signs are unexpected or prolonged bleeding, pink, red or brown urine, and red or black tarry stools (FDA). Bleeding is the main sign of an excessive acenocoumarol effect. The most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding and bleeding into the joints (acenocoumarol SmPC, overdose section, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
Clopidogrel is not recommended with oral anticoagulants because bleeding may become more severe (clopidogrel summary of product characteristics, SmPC, European Medicines Agency, EMA). The acenocoumarol SmPC also generally advises against the combination unless it is strictly indicated, for example when an oral anticoagulant and an antiplatelet drug are both needed (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the drugs are given together, use close and frequent coagulation checks with the international normalised ratio (INR), for example twice a week, including after clopidogrel is stopped (AEMPS). Watch carefully for signs of bleeding, including occult bleeding, especially in the first weeks of treatment and after cardiac or other surgery. If clinical signs of bleeding appear, promptly consider a full blood count and other appropriate tests (EMA). If the antiplatelet effect is temporarily not wanted before elective surgery, stop clopidogrel 7 days beforehand (EMA). Stopping clopidogrel increases the risk of cardiovascular events. After a necessary interruption, for example because of bleeding, restart it as soon as possible once the bleeding has stopped (clopidogrel label, US Food and Drug Administration, FDA). For significant bleeding, stop acenocoumarol and give vitamin K1 5–10 mg intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, overdose section, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica Plavix 75 mg comprimidos recubiertos con película (clopidogrel) (2022)– AEMPS CIMA, ficha técnica Plavix 75 mg, nº registro 98069001 (EU/1/98/069), texto EMA, revisión diciembre 2022, secciones 4.2, 4.4 y 4.5
- FDA: Plavix (clopidogrel) prescribing information (2025)– FDA, DailyMed setid de8b0b67-eb25-4684-83b5-7ad785314227 (Sanofi-Aventis U.S.), revised 05/2025, Boxed Warning, sections 5.2, 6.1 (Table 1, CURE), 7.2, 7.4 and 7.7
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9